JP2020183447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020183447A5 JP2020183447A5 JP2020129898A JP2020129898A JP2020183447A5 JP 2020183447 A5 JP2020183447 A5 JP 2020183447A5 JP 2020129898 A JP2020129898 A JP 2020129898A JP 2020129898 A JP2020129898 A JP 2020129898A JP 2020183447 A5 JP2020183447 A5 JP 2020183447A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- tumors
- antibody
- poliovirus
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 claims 27
- 241000991587 Enterovirus C Species 0.000 claims 13
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 claims 12
- 102100029740 Poliovirus receptor Human genes 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 241000710124 Human rhinovirus A2 Species 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 6
- 208000032612 Glial tumor Diseases 0.000 claims 5
- 206010018338 Glioma Diseases 0.000 claims 5
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 5
- 108700026244 Open Reading Frames Proteins 0.000 claims 5
- 208000005017 glioblastoma Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010061968 Gastric neoplasm Diseases 0.000 claims 4
- 201000010133 Oligodendroglioma Diseases 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 241000219793 Trifolium Species 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 210000000941 bile Anatomy 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 208000037841 lung tumor Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 4
- 208000023958 prostate neoplasm Diseases 0.000 claims 4
- 208000006274 Brain Stem Neoplasms Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 230000000112 colonic effect Effects 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000013718 rectal benign neoplasm Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 241000274177 Juniperus sabina Species 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022168742A JP2022183342A (ja) | 2015-10-15 | 2022-10-21 | 併用療法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242123P | 2015-10-15 | 2015-10-15 | |
| US62/242,123 | 2015-10-15 | ||
| US201662361725P | 2016-07-13 | 2016-07-13 | |
| US62/361,725 | 2016-07-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519304A Division JP6850290B2 (ja) | 2015-10-15 | 2016-10-14 | 併用療法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022168742A Division JP2022183342A (ja) | 2015-10-15 | 2022-10-21 | 併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020183447A JP2020183447A (ja) | 2020-11-12 |
| JP2020183447A5 true JP2020183447A5 (enExample) | 2021-05-27 |
Family
ID=58518110
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519304A Active JP6850290B2 (ja) | 2015-10-15 | 2016-10-14 | 併用療法 |
| JP2020129898A Withdrawn JP2020183447A (ja) | 2015-10-15 | 2020-07-31 | 併用療法 |
| JP2022168742A Pending JP2022183342A (ja) | 2015-10-15 | 2022-10-21 | 併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519304A Active JP6850290B2 (ja) | 2015-10-15 | 2016-10-14 | 併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022168742A Pending JP2022183342A (ja) | 2015-10-15 | 2022-10-21 | 併用療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10744170B2 (enExample) |
| EP (1) | EP3362091A4 (enExample) |
| JP (3) | JP6850290B2 (enExample) |
| CN (1) | CN108697788A (enExample) |
| WO (1) | WO2017066557A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| WO2018067446A1 (en) | 2016-10-06 | 2018-04-12 | Duke University | Detection of cd-155, the poliovirus receptor |
| US11311628B2 (en) | 2016-10-17 | 2022-04-26 | Duke University | Production of immunotoxin D2C7—(scdsFv)—PE38KDEL |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| EP3773650A4 (en) * | 2018-04-02 | 2021-12-29 | Duke University | Neoadjuvant cancer treatment |
| EP4051321A4 (en) | 2019-10-30 | 2023-11-22 | Duke University | IMMUNOTHERAPY WITH COMBINATION THERAPY INCLUDING AN IMMUNOTOXIN |
| US20220387529A1 (en) * | 2019-11-04 | 2022-12-08 | Duke University | Treatment for primary and metastatic cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8066983B2 (en) | 2008-03-14 | 2011-11-29 | The Research Foundation Of State University Of New York | Attenuated poliovirus |
| DK2806883T3 (da) * | 2012-01-25 | 2019-07-22 | Dnatrix Inc | Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation |
| US20150250837A1 (en) | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| ES2688653T3 (es) * | 2012-11-21 | 2018-11-06 | Duke University | Poliovirus oncolítico para tumores humanos |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| CA3156357A1 (en) | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| WO2015127501A1 (en) * | 2014-02-27 | 2015-09-03 | Viralytics Limited | Combination method for treatment of cancer |
-
2016
- 2016-10-14 US US15/768,147 patent/US10744170B2/en active Active
- 2016-10-14 EP EP16856268.4A patent/EP3362091A4/en active Pending
- 2016-10-14 CN CN201680060434.8A patent/CN108697788A/zh active Pending
- 2016-10-14 WO PCT/US2016/057023 patent/WO2017066557A1/en not_active Ceased
- 2016-10-14 JP JP2018519304A patent/JP6850290B2/ja active Active
-
2020
- 2020-07-31 JP JP2020129898A patent/JP2020183447A/ja not_active Withdrawn
- 2020-08-11 US US16/990,036 patent/US20200368300A1/en not_active Abandoned
-
2022
- 2022-10-21 JP JP2022168742A patent/JP2022183342A/ja active Pending
-
2023
- 2023-12-19 US US18/545,176 patent/US20240415906A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022183342A5 (enExample) | ||
| Weiler-Normann et al. | Mouse models of liver fibrosis | |
| Margulis et al. | Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus—safety lead-in results of a phase 2 trial | |
| Samuel | Relaxin: antifibrotic properties and effects in models of disease | |
| JP2021520368A5 (enExample) | ||
| JP2022533578A5 (enExample) | ||
| Igarashi et al. | Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model | |
| Maawy et al. | Photoimmunotherapy lowers recurrence after pancreatic cancer surgery in orthotopic nude mouse models | |
| Li et al. | Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo | |
| Hsu et al. | Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats | |
| Warner et al. | Therapeutic oncolytic viruses: clinical advances and future directions | |
| Patel et al. | Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1 | |
| Shih et al. | 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma | |
| CN108697788A (zh) | 组合治疗 | |
| Qazi et al. | Early multifocal recurrence of hepatoblastoma in the residual liver after R0 liver resection with ALPPS procedure: a case report | |
| US10744171B2 (en) | Sequential anti-cancer treatment | |
| JP2020522555A5 (enExample) | ||
| Iosif et al. | Gastrointestinal bleeding as initial presentation of extramedullary plasma cell neoplasms: A case report and review of the literature | |
| Habibollahi et al. | Integrated imaging probe and bispecific antibody development enables in vivo targeting of glypican-3–expressing hepatocellular carcinoma | |
| Jin et al. | Photoimmunotheranostics of epithelioid sarcoma by targeting CD44 or EGFR | |
| WO2021091964A1 (en) | Treatment for primary and metastatic cancer | |
| BR112021010516A2 (pt) | Tratamento tópico de diarreia, colite ou enterocolite induzida por inibidor de ponto de verificação imunológico usando anticorpos e fragmentos dos mesmos | |
| CN104830776A (zh) | 一种耐药型多发性骨髓瘤动物模型及其构建方法 | |
| Yokoi et al. | Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms’ tumor | |
| De Jong et al. | Radioimmunotherapy prevents local recurrence of colonic cancer in an experimental model |